loading page

Association of Toll-like receptor (TLR) 3 & 9 genes’ polymorphism with Hepatitis C virus-specific cell-mediated immunity outcome among Egyptian healthcare workers
  • +8
  • Sayed Abdelwahab,
  • Shaimaa Hamdy,
  • Ahmed Osman,
  • Zainab Zakaria,
  • Iman Galal,
  • Maha Sobhy,
  • Mohamed Hashem,
  • Walaa Allam,
  • Mohamed Abdel-Samiee,
  • Eman Rewisha,
  • Imam Waked
Sayed Abdelwahab
Minia University Faculty of Medicine

Corresponding Author:[email protected]

Author Profile
Shaimaa Hamdy
The Egyptian Holding Company for Biological Products and Vaccines
Author Profile
Ahmed Osman
Cairo University Faculty of Science
Author Profile
Zainab Zakaria
Heliopolis University for Sustainable Development
Author Profile
Iman Galal
The Egyptian Holding Company for Biological Products and Vaccines (VACSERA),
Author Profile
Maha Sobhy
The Egyptian Holding Company for Biological Products and Vaccines (VACSERA)
Author Profile
Mohamed Hashem
University of Maryland School of Medicine
Author Profile
Walaa Allam
Zewail City of Science and Technology - Zewail City Campus
Author Profile
Mohamed Abdel-Samiee
Menoufia University National Liver Institute
Author Profile
Eman Rewisha
Menoufia University National Liver Institute
Author Profile
Imam Waked
Menoufia University National Liver Institute
Author Profile

Abstract

Variations in immune responses could define successful resistance to Hepatitis C Virus (HCV) infection. Toll-like receptors (TLR)-3 are innate detectors of dsRNA viruses while TLR9 recognizes bacterial and viral unmethylated CpG motifs. We previously reported that TLR3.rs3775290 “CC” genotype was associated with HCV chronicity, while TLR9 gene played no major role in this infection. This study identified the role of TLR3.rs3775290 (c.1377C/T), TLR9.rs5743836 (-1237T→C) and TLR9.rs352140 (G2848A) gene polymorphisms in predicting the outcome of HCV-specific cell-mediated immunity (CMI) among Egyptian healthcare workers (HCWs) and patients. We enrolled 546 subjects (409 HCWs and 137 patients) divided into four groups. Group1: 265 seronegative, aviraemic subjects; group2: 25 seronegative, viraemic subjects; group3: 87 subjects with spontaneously resolved HCV infection; and group4: 169 chronic HCV HCWs and patients. All subjects were genotyped for TLR3.rs3775290, TLR9.rs5743836 and TLR9.rs352140 SNPs by PCR-restriction fragment length polymorphism (PCR-RFLP) analysis. We, also, quantified HCV-specific CMI in 265 HCWs distributed among the four groups using an interferon gamma (IFN-γ) enzyme-linked immunospot (ELISpot) assay in response to nine HCV genotype 4a overlapping 15mer peptide pools covering the whole viral genome. No statistically significant difference was found between CMI responding subjects among Egyptian HCWs with different HCV states and TLR3.rs3775290 genotype or TLR9.rs352140. However, there was a significant relationship between the outcome of the HCV-specific CMI and the TLR9.rs5743836 genotype among the responding subjects (p=0.005) and the chronic HCV patients (p=0.044). In conclusion, TLR9.rs5743836 SNP; but not TLR3.rs3775290 or TLR9.rs352140 genotypes; could predict the outcome of HCV-specific CMI responses among genotype-4-infected Egyptians.
16 Dec 2020Published in Clinical and Experimental Immunology volume 203 issue 1 on pages 3-12. 10.1111/cei.13514